<p>Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM - 获取免费报告）在周五的交易中下跌了 6.2%。该公司的股价最低曾达到 20.07 美元，最后交易价为 19.96 美元。交易期间大约交易了 558,807 股，较日均交易量 1,487,655 股下降了 62%。该股票之前的收盘价为 21.28 美元。</p>
<p>获取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>几位股票研究分析师对 TNDM 股票发布了报告。Piper Sandler 将 Tandem Diabetes Care 的股票目标价从 36.00 美元下调至 30.00 美元，并在 5 月 1 日的研究报告中给予该公司 “增持” 评级。Canaccord Genuity Group 将 Tandem Diabetes Care 的股票目标价从 58.00 美元上调至 59.00 美元，并在 5 月 1 日的研究报告中给予该股票 “买入” 评级。Mizuho 在 4 月 10 日的研究报告中开始覆盖 Tandem Diabetes Care 的股票。他们给予该公司 “中性” 评级，目标价为 20.00 美元。Sanford C. Bernstein 将 Tandem Diabetes Care 的股票评级从 “跑赢大盘” 下调至 “市场表现”，并在 2 月 28 日的研究报告中将该公司的目标价从 35.00 美元下调至 25.00 美元。最后，摩根士丹利在 3 月 3 日的研究报告中将 Tandem Diabetes Care 的目标价从 42.00 美元下调至 24.00 美元，并给予该公司 “中性” 评级。八位投资分析师对该股票给予了持有评级，八位分析师则给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 37.47 美元。</p>
<p><strong>查看我们对 Tandem Diabetes Care 的最新分析</strong></p>
<h2>Tandem Diabetes Care 下跌 6.3%</h2>
<p>该公司的市值为 13.3 亿美元，市盈率为-10.28，贝塔值为 1.47。该公司的债务与股本比率为 1.29，速动比率为 2.32，流动比率为 2.90。该公司的 50 日简单移动平均线为 19.44 美元，200 日简单移动平均线为 27.20 美元。</p>
<p>Tandem Diabetes Care（纳斯达克代码：TNDM - 获取免费报告）最近一次发布财报是在 4 月 30 日，医疗设备公司报告本季度每股收益为（0.67 美元），低于分析师的共识预期（0.60 美元）0.07 美元。该公司本季度的收入为 2.3442 亿美元，而分析师的预期为 2.2019 亿美元。Tandem Diabetes Care 的净利润率为-14.84%，股本回报率为-44.19%。该公司的季度收入较去年同期增长了 22.3%。在去年同期，该公司每股收益为（0.65 美元）。股票研究分析师预测 Tandem Diabetes Care, Inc.在本年度的每股收益将为-1.68 美元。</p>
<h2>Tandem Diabetes Care 的内部买卖情况</h2>
<p>在相关消息中，首席运营官 Jean-Claude Kyrillos 在 3 月 7 日（星期五）以每股 18.12 美元的平均价格购买了 10,538 股该股票，总交易额为 190,948.56 美元。购买后，首席运营官现在拥有 10,538 股公司股票，价值约为 190,948.56 美元。此次交易使他们的持股增加了∞。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有公司 1.90% 的股份。</p>
<h2>机构投资者对 Tandem Diabetes Care 的看法</h2>
<p>一些机构投资者最近增加或减少了在 TNDM 的持股。AlphaQuest LLC 在第四季度将其在 Tandem Diabetes Care 的持股增加了 138.7%。AlphaQuest LLC 现在拥有 931 股医疗设备公司的股票，价值 34,000 美元，此前在上个季度又购买了 541 股。Assetmark Inc.在第一季度将其在 Tandem Diabetes Care 的持股增加了 42.9%。Assetmark Inc.现在拥有 1,750 股医疗设备公司的股票，价值 34,000 美元，此前在此期间又购买了 525 股。NBC Securities Inc.在第一季度购买了 Tandem Diabetes Care 的新股份，价值约为 37,000 美元。Jones Financial Companies Lllp 在第四季度将其在 Tandem Diabetes Care 的持股增加了 195.8%。Jones Financial Companies Lllp 现在拥有 1,130 股医疗设备公司的股票，价值 41,000 美元，此前在上个季度又购买了 748 股。最后，Smartleaf Asset Management LLC 在第四季度将其在 Tandem Diabetes Care 的持股增加了 163.4%。Smartleaf Asset Management LLC 现在拥有 1,775 股医疗设备公司的股票，价值 65,000 美元，此前在上个季度又购买了 1,101 股。</p>
<h2>Tandem Diabetes Care 公司简介</h2>
<p>（获取免费报告）</p>
<p>Tandem Diabetes Care, Inc.是一家医疗设备公司，设计、开发并商业化技术解决方案，服务于美国及国际上生活在糖尿病中的人群。该公司的旗舰产品是 t:slim X2 胰岛素输送系统，这是一个用于管理胰岛素输送的平台，并能在泵的主屏幕上直接显示连续血糖监测传感器信息；以及 Tandem Mobi 胰岛素泵，这是一个自动胰岛素输送系统。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Tandem Diabetes Care</li>
<li>10 只最佳航空公司股票推荐</li>
<li>Nike 在亚马逊的扩张可能预示着 2025 年的转机</li>
<li>3 只前景良好的金融科技股票</li>
<li>英特尔的转机可能是无人关注的最佳投资</li>
<li>哪里可以找到财报电话会议记录</li>
<li>3 只将从金色圆顶中获利的防御类股票</li>
</ul>
<p><em>这条即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Tandem Diabetes Care 吗？</h2>
<p>在你考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Tandem Diabetes Care 并不在名单上。</p>
<p>虽然 Tandem Diabetes Care 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TNDM

<p>Tandem Diabetes Care（纳斯达克代码：TNDM）股价下跌 6.2%，至 19.96 美元，交易量较平均水平下降 62%。分析师们调整了目标价格，Piper Sandler 将其下调至 30.00 美元，而 Canaccord Genuity 则将其上调至 59.00 美元。该公司报告季度每股亏损 0.67 美元，未能达到预期，但收入同比增长 22.3%。内部人士的买入行为被注意到，机构投资者也在调整其在公司的持股。该股票的共识评级为 “适度买入”，目标价格为 37.47 美元</p>

<p>Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) was down 6.2% during trading on Friday . The company traded as low as $20.07 and last traded at $19.96. Approximately 558,807 shares were traded during trading, a decline of 62% from the average daily volume of 1,487,655 shares. The stock had previously closed at $21.28.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.（纳斯达克代码：TNDM - 获取免费报告）在周五的交易中下跌了 6.2%。该公司的股价最低曾达到 20.07 美元，最后交易价为 19.96 美元。交易期间大约交易了 558,807 股，较日均交易量 1,487,655 股下降了 62%。该股票之前的收盘价为 21.28 美元。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Several equities research analysts have issued reports on TNDM shares. Piper Sandler decreased their price objective on shares of Tandem Diabetes Care from $36.00 to $30.00 and set an &#34;overweight&#34; rating for the company in a research note on Thursday, May 1st. Canaccord Genuity Group upped their price target on shares of Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, May 1st. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They issued a &#34;neutral&#34; rating and a $20.00 target price for the company. Sanford C. Bernstein lowered shares of Tandem Diabetes Care from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and decreased their target price for the company from $35.00 to $25.00 in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their target price on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a &#34;neutral&#34; rating for the company in a research report on Monday, March 3rd. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $37.47.</p>
<div class="lb-trans"><p>几位股票研究分析师对 TNDM 股票发布了报告。Piper Sandler 将 Tandem Diabetes Care 的股票目标价从 36.00 美元下调至 30.00 美元，并在 5 月 1 日的研究报告中给予该公司 “增持” 评级。Canaccord Genuity Group 将 Tandem Diabetes Care 的股票目标价从 58.00 美元上调至 59.00 美元，并在 5 月 1 日的研究报告中给予该股票 “买入” 评级。Mizuho 在 4 月 10 日的研究报告中开始覆盖 Tandem Diabetes Care 的股票。他们给予该公司 “中性” 评级，目标价为 20.00 美元。Sanford C. Bernstein 将 Tandem Diabetes Care 的股票评级从 “跑赢大盘” 下调至 “市场表现”，并在 2 月 28 日的研究报告中将该公司的目标价从 35.00 美元下调至 25.00 美元。最后，摩根士丹利在 3 月 3 日的研究报告中将 Tandem Diabetes Care 的目标价从 42.00 美元下调至 24.00 美元，并给予该公司 “中性” 评级。八位投资分析师对该股票给予了持有评级，八位分析师则给予了买入评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 37.47 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Tandem Diabetes Care 的最新分析</strong></p>
</div><h2>Tandem Diabetes Care Trading Down 6.3%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 下跌 6.3%</h2>
</div><p>The firm has a market capitalization of $1.33 billion, a P/E ratio of -10.28 and a beta of 1.47. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The firm has a 50 day simple moving average of $19.44 and a two-hundred day simple moving average of $27.20.</p>
<div class="lb-trans"><p>该公司的市值为 13.3 亿美元，市盈率为-10.28，贝塔值为 1.47。该公司的债务与股本比率为 1.29，速动比率为 2.32，流动比率为 2.90。该公司的 50 日简单移动平均线为 19.44 美元，200 日简单移动平均线为 27.20 美元。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). The company had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The firm's quarterly revenue was up 22.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.65) EPS. Equities research analysts forecast that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（纳斯达克代码：TNDM - 获取免费报告）最近一次发布财报是在 4 月 30 日，医疗设备公司报告本季度每股收益为（0.67 美元），低于分析师的共识预期（0.60 美元）0.07 美元。该公司本季度的收入为 2.3442 亿美元，而分析师的预期为 2.2019 亿美元。Tandem Diabetes Care 的净利润率为-14.84%，股本回报率为-44.19%。该公司的季度收入较去年同期增长了 22.3%。在去年同期，该公司每股收益为（0.65 美元）。股票研究分析师预测 Tandem Diabetes Care, Inc.在本年度的每股收益将为-1.68 美元。</p>
</div><h2>Insider Buying and Selling at Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 的内部买卖情况</h2>
</div><p>In related news, COO Jean-Claude Kyrillos bought 10,538 shares of the stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link. Insiders own 1.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席运营官 Jean-Claude Kyrillos 在 3 月 7 日（星期五）以每股 18.12 美元的平均价格购买了 10,538 股该股票，总交易额为 190,948.56 美元。购买后，首席运营官现在拥有 10,538 股公司股票，价值约为 190,948.56 美元。此次交易使他们的持股增加了∞。该交易已在证券交易委员会的备案中披露，相关文件可通过此链接访问。内部人士持有公司 1.90% 的股份。</p>
</div><h2>Institutional Investors Weigh In On Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>机构投资者对 Tandem Diabetes Care 的看法</h2>
</div><p>A number of institutional investors have recently added to or reduced their stakes in TNDM. AlphaQuest LLC raised its holdings in shares of Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after acquiring an additional 541 shares in the last quarter. Assetmark Inc. raised its stake in shares of Tandem Diabetes Care by 42.9% during the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock worth $34,000 after buying an additional 525 shares during the period. NBC Securities Inc. purchased a new stake in shares of Tandem Diabetes Care during the first quarter worth approximately $37,000. Jones Financial Companies Lllp increased its position in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after purchasing an additional 748 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Tandem Diabetes Care by 163.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after buying an additional 1,101 shares in the last quarter.</p>
<div class="lb-trans"><p>一些机构投资者最近增加或减少了在 TNDM 的持股。AlphaQuest LLC 在第四季度将其在 Tandem Diabetes Care 的持股增加了 138.7%。AlphaQuest LLC 现在拥有 931 股医疗设备公司的股票，价值 34,000 美元，此前在上个季度又购买了 541 股。Assetmark Inc.在第一季度将其在 Tandem Diabetes Care 的持股增加了 42.9%。Assetmark Inc.现在拥有 1,750 股医疗设备公司的股票，价值 34,000 美元，此前在此期间又购买了 525 股。NBC Securities Inc.在第一季度购买了 Tandem Diabetes Care 的新股份，价值约为 37,000 美元。Jones Financial Companies Lllp 在第四季度将其在 Tandem Diabetes Care 的持股增加了 195.8%。Jones Financial Companies Lllp 现在拥有 1,130 股医疗设备公司的股票，价值 41,000 美元，此前在上个季度又购买了 748 股。最后，Smartleaf Asset Management LLC 在第四季度将其在 Tandem Diabetes Care 的持股增加了 163.4%。Smartleaf Asset Management LLC 现在拥有 1,775 股医疗设备公司的股票，价值 65,000 美元，此前在上个季度又购买了 1,101 股。</p>
</div><h2>Tandem Diabetes Care Company Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.是一家医疗设备公司，设计、开发并商业化技术解决方案，服务于美国及国际上生活在糖尿病中的人群。该公司的旗舰产品是 t:slim X2 胰岛素输送系统，这是一个用于管理胰岛素输送的平台，并能在泵的主屏幕上直接显示连续血糖监测传感器信息；以及 Tandem Mobi 胰岛素泵，这是一个自动胰岛素输送系统。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>10 Best Airline Stocks to Buy</li>
<li>Nike’s Amazon Expansion Could Signal a Turnaround in 2025</li>
<li>3 Fintech Stocks With Good 2021 Prospects</li>
<li>Intel’s Turnaround May Be the Best Bet No One’s Watching</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>3 Defense Stocks That Will Profit From a Golden Dome</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Tandem Diabetes Care</li>
<li>10 只最佳航空公司股票推荐</li>
<li>Nike 在亚马逊的扩张可能预示着 2025 年的转机</li>
<li>3 只前景良好的金融科技股票</li>
<li>英特尔的转机可能是无人关注的最佳投资</li>
<li>哪里可以找到财报电话会议记录</li>
<li>3 只将从金色圆顶中获利的防御类股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这条即时新闻提醒是由叙事科学技术和 MarketBeat 的金融数据生成的，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tandem Diabetes Care 吗？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Tandem Diabetes Care 并不在名单上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tandem Diabetes Care 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tandem Diabetes Care（NASDAQ:TNDM）股价下跌 6.2% - 现在是否应该卖出？